AbbVie Inc (ABBV)vsInsulet Corporation (PODD)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
PODD
Insulet Corporation
$153.22
+4.65%
HEALTHCARE · Cap: $10.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2066% more annual revenue ($62.82B vs $2.90B). PODD leads profitability with a 10.4% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.59. PODD earns a higher WallStSmart Score of 73/100 (B).
ABBV
Buy63
out of 100
Grade: C+
PODD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 33.9% year-over-year
Earnings expanding 159.0% YoY
Every $100 of equity generates 23 in profit
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Premium valuation, high expectations priced in
Trading at 8.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : PODD
The strongest argument for PODD centers on Revenue Growth, EPS Growth, Return on Equity. Revenue growth of 33.9% demonstrates continued momentum. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio, Price/Book.
Key Dynamics to Monitor
ABBV profiles as a value stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.13 — expect wider price swings.
PODD is growing revenue faster at 33.9% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (73/100 vs 63/100) and 33.9% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?